Rapport Therapeutics (RAPP) Institutional Ownership

$20.84

+1.83 (+9.63%)

(As of 09/18/2024 ET)

Number of Institutional Buyers (last 12 months): 11

Number of Institutional Sellers (last 12 months): 0

Get RAPP Insider Trade Alerts

Want to know when executives and insiders are buying or selling Rapport Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

RAPP Institutional Buying and Selling by Quarter

Ad WealthPress

$25,000 into $109,616 in two months?

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

Rapport Therapeutics Major Shareholders & Ownership History

Export to Excel

Reporting Date	Major Shareholder Name	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/27/2024	Logos Global Management LP	208,910	$4.86M	0.4%	N/A	0.591%
8/16/2024	Perceptive Advisors LLC	748,183	$17.40M	0.4%	N/A	2.045%
8/15/2024	The Manufacturers Life Insurance Company	75,516	$1.76M	0.0%	N/A	0.206%
8/15/2024	Millennium Management LLC	116,782	$2.72M	0.0%	N/A	0.319%
8/14/2024	Squarepoint Ops LLC	16,345	$380K	0.0%	N/A	0.045%
8/14/2024	Sandia Investment Management LP	5,000	$116K	0.2%	N/A	0.014%
8/14/2024	ARCH Venture Management LLC	3,728,738	$86.73M	31.6%	N/A	10.193%
8/14/2024	Davidson Kempner Capital Management LP	10,000	$229K	0.0%	N/A	0.027%
8/10/2024	Sofinnova Investments Inc.	1,951,562	$45.39M	2.4%	N/A	5.516%
8/9/2024	Johnson & Johnson	2,498,051	$58.11M	14.5%	N/A	7.061%
8/3/2024	TD Asset Management Inc	101,522	$2.36M	0.0%	N/A	0.287%

(Data available from 1/1/2016 forward)

RAPP Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of RAPP shares?: During the previous two years, 11 institutional investors and hedge funds held shares of Rapport Therapeutics. The most heavily invested institutionals were ARCH Venture Management LLC ($86.73M), Johnson & Johnson ($58.11M), Sofinnova Investments Inc. ($45.39M), Perceptive Advisors LLC ($17.40M), Logos Global Management LP ($4.86M), Millennium Management LLC ($2.72M), and TD Asset Management Inc ($2.36M).Learn more on RAPP's institutional investors.
Which institutional investors have been buying Rapport Therapeutics stock?: Of the 11 institutional investors that purchased Rapport Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ARCH Venture Management LLC ($3.73M), Johnson & Johnson ($2.50M), Sofinnova Investments Inc. ($1.95M), Perceptive Advisors LLC ($748.18K), Logos Global Management LP ($208.91K), Millennium Management LLC ($116.78K), and TD Asset Management Inc ($101.52K).
How much institutional buying is happening at Rapport Therapeutics?: Institutional investors have bought a total of 9,460,609 shares in the last 24 months. This purchase volume represents approximately $0.00 in transactions.